Market Research Industry Reports

Kyowa Hakko Kirin Co Ltd (4151) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Summary

Kyowa Hakko Kirin Co Ltd (Kyowa Hakko), a subsidiary of Kirin Holdings Company Limited, is a research and development (R&D) based biotechnology company. It focuses on the discovery, development, production and commercialization of pharmaceuticals and biotechnology products. The company offers drugs in the areas of nephrology, oncology, immunology and allergy, central nervous system among others. Its development pipeline consists of various protein, antibody and small molecule formulations for the treatment of neutropenia, anemia, chronic idiopathic thrombocytopenic purpura, hypertension, angina pectoris, allergic rhinitis, epilepsy, behavioral or personality disorders and others. The company operates through a network of subsidiaries in the US, Europe and Asia. Kyowa Hakko is headquartered in Tokyo, Japan.

Kyowa Hakko Kirin Co Ltd (4151) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 5
List of Figures 6
Kyowa Hakko Kirin Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Kyowa Hakko Kirin Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Kyowa Hakko Kirin Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Kyowa Hakko Kirin Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Kyowa Hakko Kirin Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Kyowa Hakko Kirin Co Ltd, Pharmaceuticals & Healthcare, Deal Details 15
Asset Purchase 15
ProStrakan Acquires Breast Cancer Product Fareston From GTx For US$22 Million 15
ProStrakan Acquires Abstral From Orexo For US$85 Million 16
Partnerships 17
LEO Pharma and LEO Pharma A/S Enter into Agreement with Kyowa Hakko Kirin 17
Kyowa Hakko Kirin Enters into Agreement with AstraZeneca 18
Aevi Genomic Medicine Expands its Agreement with Kyowa Hakko Kirin 19
Astellas Pharm, Kyowa Hakko Kirin, Daiichi Sankyo, Eisai, Ono Pharma and Chugai Pharma to Enter into Agreemet with Four Research Institutions 20
AstraZeneca Enters into Option Agreement with Kyowa Hakko Kirin 22
Japan Blood Products Enters into Agreement with Kyowa Hakko Kirin 23
Leo Pharma Enters into Distribution and Co-Promotion Agreement with Kyowa Hakko Kirin 24
NovAliX Enters Into Agreement With Kyowa Hakko Kirin To Develop Drug Candidates 25
Activiomics Extends Research Agreement With Kyowa Hakko Kirin 26
La Jolla Institute Enters Into Agreement With Kyowa Hakko Kirin California For Drug Discovery 27
NovAlix Enters Into Drug Discovery Agreement With Kyowa Hakko Kirin 28
Adimab Enters Into Antibody Discovery Agreement With Kyowa Hakko Kirin 29
Genmab Enters Into Agreement With Kyowa Hakko Kirin For Bispecific Antibodies 30
Activiomics Enters Into Research Agreement With Kyowa Hakko 31
Anchor Therapeutics Enters Into Research Agreement With Kyowa Hakko Kirin 32
FUJIFILM Forms Joint Venture With Kyowa Hakko Kirin 33
Licensing Agreements 34
Tillotts Pharma Enters into Licensing Agreement with BioWa and Lonza 34
Kyowa Hakko Kirin Enters into Licensing Agreement with Ardelyx 35
Kyowa Hakko Kirin Korea Enters into Licensing and Distribution Agreement with Panion & BF Biotech 36
Kyowa Hakko Kirin Enters into Licensing Agreement with SBI Biotech 37
ProStrakan Enters into Licensing Agreement with AstraZeneca for Moventig 38
Kyowa Hakko Kirin Enters into Licensing Agreement with Sandoz 39
Kyowa Hakko Kirin Amends Licensing Agreement with Syndax Pharma for Entinostat 40
Biowa And Lonza Enter into Licensing Agreement with arGEN-X for Potelligent CHOK1SV 42
Biowa And Lonza Enter Into Licensing Agreement With MedImmune For Potelligent CHOK1SV 44
Allakos Enters into Licensing Agreement with BioWa and Lonza Sales 45
Ultragenyx Pharma Enters Into Licensing Agreement With Kyowa Hakko Kirin For KRN23 46
Five Prime Therapeutics Enters Into Licensing Agreement With BioWa And Lonza For Potelligent CHOK1SV Cell Line 48
Aptalis Pharma Enters Into Licensing Agreement With ProStrakan For Rectiv 50
Cantargia Enters into Licensing Agreement with BioWa 51
Bristol-Myers Squibb Enters Into Licensing Agreement With Kyowa Hakko Kirin For Coniel In China 52
Biowa And Lonza Enters Into Licensing Agreement With Pfizer For Potelligent CHOK1SV 53
Orion Enters Into Licensing Agreement With ProStrakan For Fareston 54
Otsuka Pharma Enters Into Licensing Agreement With Kyowa Hakko Kirin For Saxagliptin 55
Asset Transactions 56
Aspen Japan Acquires Four Ethical Drug Brands from Kyowa Hakko Kirin 56
Acquisition 57
Sanford Health Acquires Hematech, Drug Development Company 57
Kyowa Hakko Kirin Co Ltd - Key Competitors 58
Kyowa Hakko Kirin Co Ltd - Key Employees 59
Kyowa Hakko Kirin Co Ltd - Locations And Subsidiaries 61
Head Office 61
Other Locations & Subsidiaries 61
Joint Venture 64
Recent Developments 65
Strategy And Business Planning 65
Jan 29, 2018: Kyowa Hakko Kirin Announces the Establishment of a Regional Headquarters Function for the Asia and Oceania Region in Singapore 65
Jan 31, 2017: Kyowa Hakko Kirin Establishes Kyowa Kirin Frontier 66
Financial Announcements 67
May 08, 2018: Kyowa Hakko Kirin Co: Announcement of Consolidated Financial Results Fiscal 2018 First Quarter 67
Feb 08, 2018: Kyowa Hakko Kirin: Announcement of Consolidated Financial Results Fiscal 2017 71
Oct 26, 2017: Kyowa Hakko Kirin: Fiscal 2017 Third Quarter Results 75
Sep 28, 2017: Kyowa Hakko Kirin: Financial results for Six Months Ended June 30, 2017 78
Jan 31, 2017: Kyowa Hakko Kirin Announces Consolidated Financial Results for the Year Ended December 31, 2016 81
Corporate Communications 83
Dec 22, 2017: Kyowa Hakko Kirin Announces Changes in the Representative Directors 83
Dec 01, 2017: Faron Pharmaceuticals Oy: Appointment of Chief Commercial Officer 84
Legal and Regulatory 85
Mar 22, 2018: Kyowa Hakko Kirin and BioWa Obtain Successful Settlement of United States Patent Infringement Lawsuit against Aragen Bioscience and Transposagen 85
Jan 11, 2017: New Drug Formulary Will Help Expedite Use of Agents in Clinical Trials 86
Product News 87
11/14/2017: Fasenra (benralizumab) receives US FDA approval for severe eosinophilic asthma 87
11/10/2017: Benralizumab receives positive EU CHMP opinion for severe, uncontrolled eosinophilic asthma 89
01/19/2018: Fasenra receives approval in Japan 91
01/10/2018: AstraZeneca receives EU approval of Fasenra for severe eosinophilic asthma 92
Clinical Trials 94
Dec 01, 2017: Faron Pharmaceuticals Oy: Appointment of Chief Commercial Officer 94
Sep 11, 2017: AstraZeneca presents new results identifying severe asthma patients who would benefit most from benralizumab 95
Sep 04, 2017: AstraZeneca Announces Phase III trial Data of benralizumab at European Respiratory Society International Congress 2017 97
May 22, 2017: Phase III ZONDA trial for benralizumab shows ability to reduce oral steroid use in severe asthma patients 98
Other Significant Developments 100
Jan 04, 2018: Kyowa Hakko Kirin: Notice of completion of domestic production base reorganization 100
Appendix 101
Methodology 101
About GlobalData 101
Contact Us 101
Disclaimer 101

List Of Tables

List of Tables
Kyowa Hakko Kirin Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Kyowa Hakko Kirin Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Kyowa Hakko Kirin Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Kyowa Hakko Kirin Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Kyowa Hakko Kirin Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 10
Kyowa Hakko Kirin Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
ProStrakan Acquires Breast Cancer Product Fareston From GTx For US$22 Million 15
ProStrakan Acquires Abstral From Orexo For US$85 Million 16
LEO Pharma and LEO Pharma A/S Enter into Agreement with Kyowa Hakko Kirin 17
Kyowa Hakko Kirin Enters into Agreement with AstraZeneca 18
Aevi Genomic Medicine Expands its Agreement with Kyowa Hakko Kirin 19
Astellas Pharm, Kyowa Hakko Kirin, Daiichi Sankyo, Eisai, Ono Pharma and Chugai Pharma to Enter into Agreemet with Four Research Institutions 20
AstraZeneca Enters into Option Agreement with Kyowa Hakko Kirin 22
Japan Blood Products Enters into Agreement with Kyowa Hakko Kirin 23
Leo Pharma Enters into Distribution and Co-Promotion Agreement with Kyowa Hakko Kirin 24
NovAliX Enters Into Agreement With Kyowa Hakko Kirin To Develop Drug Candidates 25
Activiomics Extends Research Agreement With Kyowa Hakko Kirin 26
La Jolla Institute Enters Into Agreement With Kyowa Hakko Kirin California For Drug Discovery 27
NovAlix Enters Into Drug Discovery Agreement With Kyowa Hakko Kirin 28
Adimab Enters Into Antibody Discovery Agreement With Kyowa Hakko Kirin 29
Genmab Enters Into Agreement With Kyowa Hakko Kirin For Bispecific Antibodies 30
Activiomics Enters Into Research Agreement With Kyowa Hakko 31
Anchor Therapeutics Enters Into Research Agreement With Kyowa Hakko Kirin 32
FUJIFILM Forms Joint Venture With Kyowa Hakko Kirin 33
Tillotts Pharma Enters into Licensing Agreement with BioWa and Lonza 34
Kyowa Hakko Kirin Enters into Licensing Agreement with Ardelyx 35
Kyowa Hakko Kirin Korea Enters into Licensing and Distribution Agreement with Panion & BF Biotech 36
Kyowa Hakko Kirin Enters into Licensing Agreement with SBI Biotech 37
ProStrakan Enters into Licensing Agreement with AstraZeneca for Moventig 38
Kyowa Hakko Kirin Enters into Licensing Agreement with Sandoz 39
Kyowa Hakko Kirin Amends Licensing Agreement with Syndax Pharma for Entinostat 40
Biowa And Lonza Enter into Licensing Agreement with arGEN-X for Potelligent CHOK1SV 42
Biowa And Lonza Enter Into Licensing Agreement With MedImmune For Potelligent CHOK1SV 44
Allakos Enters into Licensing Agreement with BioWa and Lonza Sales 45
Ultragenyx Pharma Enters Into Licensing Agreement With Kyowa Hakko Kirin For KRN23 46
Five Prime Therapeutics Enters Into Licensing Agreement With BioWa And Lonza For Potelligent CHOK1SV Cell Line 48
Aptalis Pharma Enters Into Licensing Agreement With ProStrakan For Rectiv 50
Cantargia Enters into Licensing Agreement with BioWa 51
Bristol-Myers Squibb Enters Into Licensing Agreement With Kyowa Hakko Kirin For Coniel In China 52
Biowa And Lonza Enters Into Licensing Agreement With Pfizer For Potelligent CHOK1SV 53
Orion Enters Into Licensing Agreement With ProStrakan For Fareston 54
Otsuka Pharma Enters Into Licensing Agreement With Kyowa Hakko Kirin For Saxagliptin 55
Aspen Japan Acquires Four Ethical Drug Brands from Kyowa Hakko Kirin 56
Sanford Health Acquires Hematech, Drug Development Company 57
Kyowa Hakko Kirin Co Ltd, Key Competitors 58
Kyowa Hakko Kirin Co Ltd, Key Employees 59
Kyowa Hakko Kirin Co Ltd, Other Locations 61
Kyowa Hakko Kirin Co Ltd, Subsidiaries 62
Kyowa Hakko Kirin Co Ltd, Joint Venture 64

List Of Figures

List of Figures
Kyowa Hakko Kirin Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Kyowa Hakko Kirin Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Kyowa Hakko Kirin Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Kyowa Hakko Kirin Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Kyowa Hakko Kirin Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Kyowa Hakko Kirin Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Kyowa Hakko Kirin Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Kyowa Hakko Kirin Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Kyowa Hakko Kirin Co Ltd (4151) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Kyowa Hakko Kirin Co Ltd (Kyowa Hakko), a subsidiary of Kirin Holdings Company Limited, is a research and development (R&D) based biotechnology company. It focuses on the discovery, development, production

USD 250View Report

KYOWANISSEI CO Ltd Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

KYOWANISSEI CO Ltd Company Profile is a detailed strategic and analytical report on KYOWANISSEI CO Ltd. The 2018 version of the report offers detailed insights into the companys strategies, developments,

USD 200View Report

Kyowa Hakko Kirin Co Ltd Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Kyowa Hakko Kirin Co Ltd Company Profile is a detailed strategic and analytical report on Kyowa Hakko Kirin Co Ltd. The 2018 version of the report offers detailed insights into

USD 200View Report

Kyowa Hakko Kirin Co, Ltd Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Kyowa Hakko Kirin Co, Ltd Company Profile is a detailed strategic and analytical report on Kyowa Hakko Kirin Co, Ltd. The 2018 version of the report offers detailed insights into

USD 200View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 250
  • Site Licence    USD 500
  • Enterprise Wide Licence    USD 750
$ 250

Reports Details

Published Date : Jul 2018
No. of Pages :101
Country :Japan
Category :Company Profiles
Publisher :GlobalData
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube